NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Lantern Pharma Inc. (LTRN) Stock Analysis

Lantern Pharma Inc. (LTRN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

LTRN

$1.91

+$0.03 (+1.87%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LTRN with… →

LTRN Key Statistics

As of Sep 4, 2026
Trading
Open
$1.86
Previous Close
$1.87
Day's Range
1.83–1.93
52-Week Range
1.11–4.70
Volume
134.50K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.30
Valuation
Market Cap
$24.35M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.63
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$17.12M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
12.78M
1-Year Return
−54.64%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
145.15K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

LTRN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−37.13%
2025−5.02%
2024−25.47%
2023−29.14%
2022−24.31%
2021−58.55%
2020 (partial year)+28.76%

As of September 4, 2026.

LTRN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$17.12M—
2024$0.00−$20.78M—
2023$0.00−$15.96M—
2022$0.00−$14.26M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$17.98M−$17.12M—
2024$0.00—−$22.22M−$20.78M—
2023$0.00—−$17.88M−$15.96M—
2022$0.00—−$14.43M−$14.26M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LTRN Valuation vs Biotechnology Median

Median of 656 stocks
MetricLTRNBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lantern Pharma Inc. (LTRN) is capitalised at $24.35M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 16 employees.

The most recent close on file for LTRN is $1.91, dated September 4, 2026. That is +$0.03 (+1.87%) against the previous close. The 52-week range on file runs from $1.11 to $4.70. The latest close sits 71.62% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $17.12M. Profit margin runs at 0%. Trailing earnings per share are −1.63.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is 2.3. Daily returns over the trailing 6 years annualize to a volatility of 84.36%. The trailing one-year price return is −54.64%. Measured over 5 years, that is −33.09% a year compounded.

Growth & Income

No dividend is on file for LTRN.

2026 is still running; the price is −37.13% year to date. Across the complete calendar years on file, 2025 returned −5.02% and 2021 returned −58.55%. Of the 5 complete calendar years on file, 0 finished higher.

Peer Comparison

Lantern Pharma Inc. (LTRN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lantern Pharma Inc. LTRN $24.35M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Lantern Pharma Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Lantern Pharma Inc.

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Visit website →